CDER Soundly Rejects Oncopeptides’ Pepaxto Appeal

In the latest in an ongoing dispute, CDER has strongly rejected Oncopeptides’ appeal of the agency’s attempt to request the drugmaker withdraw its multiple myeloma therapy Pepaxto (melphalan flufenamide).
Source: Drug Industry Daily